Abstract
The cocrystal approach has been extensively investigated over the last decade as one of the most promising methods toward modifying the dissolution behavior of insoluble drug substances. This study demonstrates that the polymorphism of pharmaceutical cocrystalline powders prepared via antisolvent methods can be controlled using kinetic parameters. A carbamazepine-saccharin (CBZ-SAC) cocrystal was selected as a model drug in this study. This crystal was manufactured through a scaled-up antisolvent process with a total solution volume of 4.5 L. CBZ-SAC cocrystal crystalline powders were synthesized by adding 3 L of water as the antisolvent into 1.5 L of CBZ and SAC in methanol, whereby the antisolvent addition rate and the agitation speed were varied as the principal kinetic parameters. To investigate how cocrystallization proceeds under each condition, periodical sampling was combined with off-line characterization and in-line near-infrared (NIR) measurements to monitor the progress of reaction over the 120-minute process. We found that the creation of form-I was preferred when the addition speed or agitation speed was increased, but a highly pure form-II resulted if kinetic conditions were reversed. These differences in polymorphism can be explained by changes in kinetic characteristics when the process is monitored by NIR. This study is directly applicable to the industrial synthesis of these types of materials, precisely when specific CBZ-SAC cocrystalline polymorphs must be manufactured on a large scale.
Similar content being viewed by others
References
FDA, Guidance for industry; Regulatory classification of pharmaceutical co-crystals, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (2013).
N. J. Babu and A. Nanjia, Cryst. Growth Des., 11, 2662 (2011).
N. Qiao, M. Li, W. Schlindwein, N. Malek, A. Davies and G. Trappitt, Int. J. Pharm., 419, 1 (2011).
H. G. Brittain, J. Pharm. Sci., 102, 311 (2013).
J.W. Steed, Trend Pharmacol. Sci., 34, 185 (2013).
R. Thakuria, A. Delori, W. Jones, M. P. Lipert, L. Roy and N. Rodríguez-Hornedo, Int. J. Pharm., 453, 101 (2013).
L. Padrela, M. A. Rodrigues, S. P. Velaga, H. A. Matos and E. G. deAzevedo, Eur. J. Pharm. Sci., 38, 9 (2009).
J. H. ter Horst and P.W. Cains, Cryst. Growth Des., 8, 2537 (2008).
R. S. Dhumal, S. V. Biradar, A. R. Paradkar and P. York, Int. J. Pharm., 368, 129 (2009).
A. Alhalaweh and S. P. Velaga, Cryst. Growth Des., 10, 3302 (2010).
J. H. ter Horst, M. A. Deij and P.W. Cains, Cryst. Growth Des., 9, 1531 (2009).
K. Yamamoto, S. Tsutsumi and Y. Ikeda, Int. J. Pharm., 437, 162 (2012).
P. P. Bag, M. Patni and C.M. Reddy, CrystEngComm, 13, 5650 (2011).
W.W. Porter III, S. C. Elie and A. J. Matzger, Cryst. Growth Des., 8, 14 (2008).
T. K. Wu, S.Y. Lin, H. L. Lin and Y.T. Huang, Bioorg. Med. Chem. Lett., 21, 3148 (2011).
D. J. Good and N. Rodriguez-Hornedo, Cryst. Growth Des., 9, 2252 (2009).
A. B.M. Buanz, G.N. Parkinson and S. Gaisford, Cryst. Growth Des., 11, 1177 (2011).
W. Limwikrant A. Nagai, Y. Hagiwara, K. Higashi, K. Yamamoto and K. Moribe, Int. J. Pharm., 431, 237 (2012).
T. Rager and R. Hilfiker, Cryst. Growth Des., 10, 3237 (2010).
G.D. Profio, V. Grosso, A. Caridi, R. Caliandro, A. Guagliardi, G. Chita, E. Curcio and E. Drioli, CrystEngComm, 13, 5670 (2011).
A. Caridi, G. Di Profio, R. Caliandro, A. Guagliardi, E. Curcio and E. Drioli, Cryst. Growth Des., 12, 4349 (2012).
A.Y. Sheikh, S. A. Rahim, R.B. Hammond and K. J. Roberts, CrystEngComm, 11, 501 (2009).
I.-C. Wang, M.-J. Lee, S.-J. Sim, W.-S. Kim, N.-H. Chun and G. J. Choi, Int. J. Pharm., 450, 311 (2013).
M.-J. Lee, N.-H. Chun, I.-C. Wang, J. J. Liu, M.-Y. Jeong and G. J. Choi, Cryst. Growth Des., 13, 2067 (2013).
N.-H. Chun, I.-C. Wang, M.-J. Lee, Y.-T. Jung, S.-k. Lee, W.-S. Kim and G. J. Choi, Eur. J. Pharm. Biopharm., 85, 854 (2013).
S. K. Pagire, S. A. Korde, B.R. Whiteside, J. Kendrick and A. Paradkar, Cryst. Growth Des., 13, 4162 (2013).
E. Lu, N. Rodríguez-Hornedo and R. Suryanarayanan, CrystEng-Comm, 10, 665 (2008).
Author information
Authors and Affiliations
Corresponding author
Additional information
These two authors equally made significant contribution to this study.
Rights and permissions
About this article
Cite this article
Lee, MJ., Wang, IC., Kim, MJ. et al. Controlling the polymorphism of carbamazepine-saccharin cocrystals formed during antisolvent cocrystallization using kinetic parameters. Korean J. Chem. Eng. 32, 1910–1917 (2015). https://doi.org/10.1007/s11814-014-0384-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11814-014-0384-9